<front xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><journal-meta><journal-id journal-id-type="publisher-id">JITC</journal-id><journal-title-group><journal-title>Journal of Interventional Cardiology</journal-title></journal-title-group><issn pub-type="epub">1540-8183</issn><issn pub-type="ppub">0896-4327</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2022/9154048</article-id><article-id pub-id-type="publisher-id">9154048</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Trans-myocardial Extraction of Endothelin-1 Correlates with Increased Microcirculatory Resistance following Percutaneous Coronary Intervention</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1442-4835</contrib-id><name><surname>Abraham</surname><given-names>George R.</given-names></name><email>george.abraham@nhs.net</email><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6212-9518</contrib-id><name><surname>Nyimanu</surname><given-names>Duuamene</given-names></name><email>dn331@medschl.cam.ac.uk</email><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4673-1602</contrib-id><name><surname>Kuc</surname><given-names>Rhoda E.</given-names></name><email>rek22@medschl.cam.ac.uk</email><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9254-7040</contrib-id><name><surname>Maguire</surname><given-names>Janet J.</given-names></name><email>jjm1003@medschl.cam.ac.uk</email><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2096-3117</contrib-id><name><surname>Davenport</surname><given-names>Anthony P.</given-names></name><email>apd10@medschl.cam.ac.uk</email><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3530-3808</contrib-id><name><surname>Hoole</surname><given-names>Stephen P.</given-names></name><email>s.hoole@nhs.net</email><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="Academic Editor"><name><surname>Zhou</surname><given-names>Shenghua</given-names></name></contrib></contrib-group><aff id="I1"><sup>1</sup><addr-line>Royal Papworth Hospital NHS Foundation Trust</addr-line><addr-line>Cambridge</addr-line><country>UK</country></aff><aff id="I2"><sup>2</sup><addr-line>Division of Experimental Medicine and Immunotherapeutics</addr-line><addr-line>University of Cambridge</addr-line><addr-line>Cambridge</addr-line><country>UK</country><ext-link ext-link-type="domain-name">cam.ac.uk</ext-link></aff><pub-date pub-type="publication-year"><year>2022</year></pub-date><pub-date pub-type="archival-date"><day>19</day><month>9</month><year>2022</year></pub-date><volume>2022</volume><history><date date-type="received"><day>17</day><month>6</month><year>2022</year></date><date date-type="rev-recd"><day>15</day><month>8</month><year>2022</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2022</year></date><date date-type="pub"><day>19</day><month>9</month><year>2022</year></date></history><permissions><copyright-year>2022</copyright-year><copyright-holder>Copyright &#xa9; 2022 George R. Abraham et al.</copyright-holder><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the <ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><italic>Objective</italic>. Coronary microvascular dysfunction (CMD) can complicate successful percutaneous coronary intervention (PCI). The potent endogenous vasoconstrictor peptide Endothelin-1 (ET-1) may be an important mediator. To investigate the mechanism, we sought to define the peri-procedural trans-myocardial gradient (TMG-coronary sinus minus aortic root levels) of ET-1 and its precursor peptide &#x2013; Big ET-1. We then assessed correlation with pressure-wire indices of CMD: coronary flow reserve (CFR) and index of microvascular resistance (IMR). <italic>Methods</italic>. Paired blood samples from the guide catheter and coronary sinus were collected before and after pressure-wire-guided PCI from patients with stable angina. Plasma was analysed using a specific enzyme-linked immunosorbent assay for quantification of ET-1 peptides and correlated with pressure-wire data. Non normally distributed continuous variables are presented as median [IQR]. <italic>Results</italic>. ET-1 and Big ET-1 increased post-PCI in the aorta (ET-1: 0.98 [0.76&#x2013;1.26] pg/ml to 1.20 [1.03&#x2013;1.67] pg/ml, <inline-formula><mml:math id="M1"><mml:mi>P</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.001</mml:mn></mml:math></inline-formula> and Big ET-1: 2.74 [1.78&#x2013;2.50] pg/ml to 3.36 [2.33&#x2013;3.97] pg/ml, <inline-formula><mml:math id="M2"><mml:mi>P</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.001</mml:mn></mml:math></inline-formula>) and coronary sinus (ET-1: 1.00 [0.81&#x2013;1.28] pg/ml to 1.09 [0.91&#x2013;1.30] pg/ml, <inline-formula><mml:math id="M3"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.03</mml:mn></mml:math></inline-formula> and Big ET-1: 2.89 [1.95&#x2013;3.83] pg/ml to 3.56 [2.66&#x2013;4.83] pg/ml, <inline-formula><mml:math id="M4"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:math></inline-formula>). TMG of ET-1 shifted negatively compared with baseline following PCI reflecting significantly increased extraction (0.03 [&#x2212;0.12&#x2013;0.17] pg/ml pre-PCI versus &#x2212;0.16 [&#x2212;0.36&#x2013;0.07] pg/ml post-PCI, <inline-formula><mml:math id="M5"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:math></inline-formula>). Increased ET-1 trans-myocardial extraction correlated with higher IMR (Pearson&#x2019;s <italic>r</italic>&#x2009;=&#x2009;0.293, <inline-formula><mml:math id="M6"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.02</mml:mn></mml:math></inline-formula>) and increased hyperemic transit time (Pearson&#x2019;s <italic>r</italic>&#x2009;=&#x2009;0.333, <inline-formula><mml:math id="M7"><mml:mi>P</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.01</mml:mn></mml:math></inline-formula>). In subgroup analysis, mean ET-1 trans-myocardial extraction was higher amongst patients with high IMR compared with low IMR (0.73&#x2009;pg/ml, SD:0.78 versus 0.17&#x2009;pg/ml, SD:0.42, <inline-formula><mml:math id="M8"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.02</mml:mn></mml:math></inline-formula>). There was additionally a numerical trend towards increased ET-1 trans-myocardial extraction in subgroups of patients with low CFR and in patients with Type 4a Myocardial Infarction, albeit not reaching statistical significance. <italic>Conclusions</italic>. Circulating ET-1 increases post-PCI and upregulated ET-1 trans-myocardial extraction contributes to increased microcirculatory resistance.</p></abstract><funding-group><award-group><funding-source>The Jon Moulton Charity Trust</funding-source><award-id>203814/Z/16/A, DN, APD</award-id></award-group><award-group><funding-source xlink:href="http://dx.doi.org/10.13039/501100000274">British Heart Foundation</funding-source><award-id>TG/18/4/33770</award-id></award-group><award-group><funding-source xlink:href="http://dx.doi.org/10.13039/501100018956">NIHR Cambridge Biomedical Research Centre</funding-source></award-group><award-group><funding-source xlink:href="http://dx.doi.org/10.13039/501100000735">University of Cambridge</funding-source><award-id>RG64226</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><ref-count count="24"/><page-count count="7"/></counts></article-meta></front>